MedTrace Logo

Extrinsic and Intrinsic Factors in Atopic Dermatitis Upon Systemic Immune Modulation

NCT05098821 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2024-08-21

No results posted yet for this study

Summary

Currently, patients with moderate to severe atopic dermatitis are treated with dupilumab if unresponsive to topical treatment. However, not all patients who suffer from atopic dermatitis respond similarly to this treatment. Pattern recognition of immune cells (PRI) is an efficient method to screen patients to allow a more personalized therapy.

The main aim of this scientific explorative study is to unravel the changes in peripheral blood immune cell compositions in patients with atopic eczema undergoing dupilumab treatment. This allows the identification of phenotypes of treatment responders and non-responders and possible approaches of treatment modifications for non-responders.

Conditions

Interventions

OTHER

not applicable, observational study

Patients undergoing systemic therapy according to international accepted guidelines for the therapy of atopic dermatitis, observational study

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • LEO Pharma

    collaborator INDUSTRY

  • Charite University, Berlin, Germany

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05098821 on ClinicalTrials.gov